Interview: Francesco di Marco – General Manager, Amgen Italy
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Address: Viale Shakespeare, 47 – 00144 Rome,Italy
Tel: +39.06.592.64.43
Sigma-tau is a leading Italian pharmaceutical group, established in 1957 that counts today 2432 employees worldwide amongst whom about 400 researchers. It reached a turnover of 605 million euros in 2008.
The headquarters of the group are in Pomezia, and Sermoneta – in the province of Latina- has active installations Biosint for the production of pharmaceutical raw materials, of L-carnitine and its derivatives.
In 2001 was established BiofuturaPharma, based in Milan, that aims to develop pharmaceuticals for the treatment of diseases of the central nervous system and respiratory system. Recently the business has extended to the development and commercialization of products derived from the biological system of carnitine.
Sigma-Tau works through the National Organization for Rare Disorders (NORD) to provide patient assistance programs to help ensure that patients who are underinsured or otherwise financially limited receive their products at little or no cost.
Always investing in research, 16% of turnover in 2008, Sigma-tau aims to continue its development by:
* Increasing commitment to research in biopharma
* Continuous technological upgrading of production systems
* High-quality products
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Galderma Italy was a founding European affiliate for the company and has seen incredible growth in the past two decades. Managing Director Bernat Albinyana discusses the affiliate’s performance, its business…
Dr. Ermano Buratti, General Manager for Astellas Pharma in Italy, discusses the company’s evolution as it enters its second decade, the importance of partnering with the government on reimbursement, the…
In 2008 Focus Reports interviewed Mr. Federico Seghi Recli as he prepared to transform Molteni Farmaceutici into an International specialty pharma company. Today we catch up on the progress, investments…
The General Manager for Eli Lilly Italy, discusses how the company’s continuous commitment to Italy has benefited the organization, the promise the country holds if certain barriers can be overcome, and how Lilly’s…
The CEO of MSD Italy discusses the company’s promising pipeline, its plans to realize growth through the launch of innovative new drugs in 2016, the paths towards a sustainable healthcare…
The MD of the Spanish Chamber of Commerce in Italy takes stock of the prevailing business winds between the two countries as both economies complete their emergence from the shadow of…
Massimo Visentin, Country Leader for Pfizer Italy, discusses the company’s remarkable success in 2015, his hopes and ambitions for the new year, and the need of the industry and Pfizer…
Prof. Luigi Naldini, Director of TIGET, discusses the success of the institute and the groundbreaking partnerships it has formed with the pharmaceutical industry, as well as his ambitions for TIGET…
Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics…
Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently…
Chris Juliam, Managing Director for Takeda Italy, shares the strategy the company is pursuing in the country, the effects market-access issues are having on innovators and patients, and what new…
See our Cookie Privacy Policy Here
